Freeman, David S.

English

University of Montana

University of Montana ScholarWorks at University of Montana Syllabi Course Syllabi Spring 2-1-2007 BMED 328.01: Antimicrobial Agents David S. Freeman University of Montana - Missoula Follow this and additional works at: https://scholarworks.umt.edu/syllabi Let us know how access to this document benefits you. Recommended Citation Freeman, David S., "BMED 328.01: Antimicrobial Agents" (2007). Syllabi. 11126. https://scholarworks.umt.edu/syllabi/11126 This Syllabus is brought to you for free and open access by the Course Syllabi at ScholarWorks at University of Montana. It has been accepted for inclusion in Syllabi by an authorized administrator of ScholarWorks at University of Montana. For more information, please contact scholarworks@mso.umt.edu. BMED 328 (ANTIMICROBIAL AGENTS)  SPRING SEMESTER, 2007  INSTRUCTORS:  David Freeman, Office - SB 308, Phone: 243-4772, E-mail: david.freeman@umontana.edu              Office Hours:  Tuesday and Thursday, 11:00 - 1:00 p.m. and Friday, 1:10 - 4:00 p.m.         Jean Pfau, Office – SB 152C, Phone: 243-4529, E-mail: jean.pfau@umontana.edu EXAMS AND GRADING:   First Exam:  Wednesday, FEB. 14 . . . . . . 60 points   Second Exam: Friday, MAR. 23 . . . . . . 80 points   Third Exam:  Friday, APRIL 27  . . . . . . 80 points   Final Exam:  Monday, MAY 7          . . . . . 100 points    10 Point Quizzes:   Best 5 or 6 out of 6 scores. .  50 or 60 points    Total Points: 370 or 380   A>92%  A->90%  B+>88%  B>82%  B->80%  C+>78%  C>72%  C->70%  D>65%  1. All EXAMS are comprehensive 2. All exams and quizzes must be taken at scheduled times 3. Instructor must be informed BEFORE missing a scheduled exam period for GOOD REASONS 4. Missed exam periods must be made up within 2 days 5. Corrections to exams or quizzes must be requested within 7 days after returning  STUDENT PERFORMANCE OBJECTIVES:     1) Know the normal relevant biochemical pathways and the major biochemical mechanisms      of action for the different classes of drugs    2) Know the biochemical mechanisms involved in the development of resistance to different     classes of antimicrobial agents    3) Given a representative chemical structure or name of a drug, know its biochemical mechanisms of action and for development of resistance     4) Given a representative chemical structure or name of a drug, know its major chemical, pharmacologic, or therapeutic categorization    5) Given a representative chemical structure or name of a drug, know its major therapeutic uses and spectrum of activity    6) Given a representative chemical structure or name of a drug, know important aspects of its absorption, pharmacokinetics, and metabolism    7) Know important chemical features (i.e., polar or lipophilic properties, labile groups, etc.) that affect the absorption, distribution, metabolism, elimination, potency, stability, or formulation of a class of antimicrobial agents    8) Given the chemical structure of an antimicrobial agent, know important chemical changes that will predictably alter its properties (i.e., potency, duration of action, stability, etc.)    9) Given a representative chemical structure or name of a drug, know its most common or serious adverse or side effects   REQUIRED TEXT:  Goodman & Gilman, "The Pharmacological Basis of Therapeutics", 11TH  Edition   Reading                                                          in Text  1095-1109 I. General Considerations, Categorization, and    Sensitivity Testing of Antimicrobial Agents  The following areas will be covered for each outline topic below: 1. General Chemical Structures and Properties of Agents 2. Biochemical Mechanisms of Action for Agents 3. Biochemical Mechanisms Involved in the Development of Microbial Resistance 4. Important Aspects of Absorption, Distribution, Metabolism, and Elimination for Agents 5. Antimicrobial Spectrum of Activity for Agents 6. Important Adverse Effects and Drug Interactions for Agents   Text   II.  Antibacterial Agents 1111-1118  A.  Sulfonamides and TRIMETHOPRIM 1119-1122  B.  Quinolones, Fluoroquinolones 1122-1124  C.  METHENAMINE and NITROFURANTOIN    D.  Beta-lactam Antibiotics 1127-1143         1. Penicillins 1151-1152         2. Beta-lactamase inhibitors (CLAVULANIC ACID, SULBACTAM, TAZOBACTAM) 1143-1150         3. Cephalosporins 1150-1151         4. Carbapenems (IMIPENEM, MEROPENEM, ERTAPENEM) 1151          5.  Monobactams (AZTREONAM)  1193-1199  E.  VANCOMYCIN, TEICHOPLANIN, DAPTOMYCIN,      POLYMYXIN, BACITRACIN, MUPIROCIN 1155-1168, 1193 F.  Aminoglycosides, SPECTINOMYCIN 1173-1179  G.  Tetracyclines, Glycylcyclines (TIGECYCLINE) 1182-1187  H.   Macrolides (ERYTHROMYCIN, AZITHROMYCIN, CLARITHROMYCIN) 1187-1188  I.   Ketolides (TELITHROMYCIN) 1179-1182  J.  CHLORAMPHENICOL 1188-1190  K.   CLINDAMYCIN 1190-1191  L.  Streptogramins (QUINUPRISTIN, DALFOPRISTIN) 1192-1193  M.  Oxazolidinones (LINEZOLID) 1057-1060  N.  METRONIDAZOLE    III.  Anti-mycobacterial Agents 1203-1214  A. Drugs for Tuberculosis  (ISONIAZID, RIFAMPIN, PYRAZINAMIDE, ETHAMBUTOL) 1216-1218  B. Drugs for Mycobacterium Avium Complex Infections    IV.  Antifungal Agents 1225-1230  A. AMPHOTERICIN B and FLUCYTOSINE 1230-1234  B. Azole Antifungals - Imidazoles and Triazoles (KETOCONAZOLE, FLUCONAZOLE,      ITRACONAZOLE, VORICONAZOLE, POSACONAZOLE) 1235   C. Echinocandins (CASPOFUNGIN, MICAFUNGIN, ANIDULAFUNGIN) 1235-1240  D. Miscellaneous and Topical Antifungal Agents  (GRISEOFULVIN, TERBINAFINE,        CLOTRIMAZOLE, MICONAZOLE, TOLNAFTATE, NYSTATIN, UNDECYLENIC ACID)    V.  Antiviral Agents 1243-1245  A. Overview of Viral DNA and RNA Biochemical Processes 1247-1248  B. Overview of Biochemical Mechanisms of Action and Resistance Development 1246-1256  C. Non-HIV Antiviral Agents  (ACYCLOVIR, VALACYCLOVIR, CIDOFOVIR,       DOCOSANOL, FAMCICLOVIR, PENCICLOVIR, FOMIVIRSEN, FOSCARNET,     GANCICLOVIR, VALGANCICLOVIR, TRIFLURIDINE, VIDARABINE) 1256-1260  D. Antiinfluenza Agents (AMANTADINE, RIMANTIDINE, OSELTAMIVIR, ZANAMIVIR) 1260-1268  E. Antihepatitis Agents, Other Antiviral Agents, and New Strategies  VI. HIV Antiviral Agents 1273-1275  A. Overview of HIV Infection  1276-1280  B. History and Principles of HIV Chemotherapy 1280-1292  C. Nucleoside Reverse Transcriptase Inhibitors    (ABACAVIR, DIDANOSINE,     EMTRICITABINE, LAMIVUDINE, STAVUDINE, TENOFOVIR,     ZALCITABINE, ZIDOVUDINE)  1292-1297  D. Nonnucleoside Reverse Transcriptase Inhibitors     (DELAVIRDINE, EFAVIRENZ, NEVIRAPINE) 1297-1308  E. HIV Protease Inhibitors  (AMPRENAVIR, ATAZANAVIR, DARUNAVIR,       FOSAMPRENAVIR, INDINAVIR, LOPINAVIR, NELFINAVIR, RITONAVIR,     SAQUINAVIR, TIPRANAVIR) 1308-1310  F. Entry Inhibitors (ENFUVIRTIDE) and New Drugs in Development 

BMED 328.01: Antimicrobial Agents

https://scholarworks.umt.edu/cgi/viewcontent.cgi?article=12036&amp;context=syllabi

BMED 328.01: Antimicrobial Agents

Abstract

Similar works

Full text

Available Versions

University of Montana